Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

被引：0
作者：
Cornelia Kolberg-Liedtke
Friedrich Feuerhake
Madlen Garke
Matthias Christgen
Ronald Kates
Eva Maria Grischke
Helmut Forstbauer
Michael Braun
Mathias Warm
John Hackmann
Christoph Uleer
Bahriye Aktas
Claudia Schumacher
Sherko Kuemmel
Rachel Wuerstlein
Monika Graeser
Ulrike Nitz
Hans Kreipe
Oleg Gluz
Nadia Harbeck
机构：
[1] University Hospital Essen,Department of Gynecology and Obstetrics
[2] Medical School Hannover,Institute of Pathology
[3] University Hospital Luebeck,Women’s Clinic
[4] West German Study Group,Breast Center
[5] University Clinics Tuebingen,Breast Center
[6] Practice Network Troisdorf,Breast Center
[7] Rotkreuz Clinics Munich,Department of Gynecology
[8] City Hospital Holweide,Breast Center
[9] Marien-Hospital,Breast Unit
[10] Practice of Gynecology and Oncology,Department of Gynecology with Breast Center
[11] University Hospital Leipzig,Breast Center
[12] St. Elisabeth Hospital,Breast Center Niederrhein
[13] Kliniken Essen-Mitte,undefined
[14] Charité – Universitätsmedizin Berlin,undefined
[15] LMU University Hospital,undefined
[16] University Hospital Hamburg-Eppendorf,undefined
[17] Ev. Hospital Bethesda,undefined
来源：
Breast Cancer Research | / 24卷
关键词：
Triple-negative breast cancer; sTils; Neoadjuvant chemotherapy; Pathologic complete response; 3-Week biopsy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 236 条
  • [1] Gluz O(2009)Triple-negative breast cancer–current status and future directions Ann Oncol 20 1913-1927
  • [2] Liedtke C(2013)The prognostic impact of age in patients with triple-negative breast cancer Breast Cancer Res Treat 138 591-599
  • [3] Gottschalk N(2007)The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329-2334
  • [4] Liedtke C(2008)Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275-1281
  • [5] Hess KR(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-172
  • [6] Karn T(2016)The role of neoadjuvant trials in drug development for solid tumors Clin Cancer Res 22 2323-2328
  • [7] Carey LA(2019)Window of opportunity trials for biomarker discovery in breast cancer Curr Opin Oncol 31 486-492
  • [8] Dees EC(2018)Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results J Natl Cancer Inst 110 628-637
  • [9] Sawyer L(2016)Clinical relevance of host immunity in breast cancer: From TILs to the clinic Nat Rev Clin Oncol 13 228-241
  • [10] Liedtke C(2019)Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers J Clin Oncol 37 559-569
12345678910